Telix director files initial Form 3

Telix Pharmaceuticals Ltd director William R. Jellison has filed an initial Form 3, which is a statement of beneficial ownership for company insiders.

Accepted by SEC EDGAR 05/18/2026 - 06:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd director William R. Jellison has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists him as a director but does not report any share transactions or holdings changes, serving mainly as a baseline disclosure.

Key Terms

Form 3, reportingPersons, transactionSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Jellison William R" } ]"

transactionSummary financial

""transactionSummary": { "buyCount": 0, "sellCount": 0 }"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Telix Pharmaceuticals (TLX) Form 3 filing for William R. Jellison indicate?

The Form 3 shows that William R. Jellison is a director of Telix Pharmaceuticals Ltd. It is an initial statement of beneficial ownership and, in this case, reports no stock transactions or changes in holdings for the reporting person.

Did William R. Jellison buy or sell Telix Pharmaceuticals (TLX) shares in this Form 3?

No transactions are reported in this Form 3 filing. The transaction summary shows zero buys, zero sells, and no other acquisitions or dispositions, meaning it functions purely as an initial ownership baseline for this director.

What roles does the reporting person hold in the Telix Pharmaceuticals (TLX) Form 3?

The reporting person, William R. Jellison, is identified as a director of Telix Pharmaceuticals Ltd and not an officer or ten percent owner. This clarifies his governance role without indicating any specific equity transactions in this filing.

Are there any derivative securities reported in the Telix Pharmaceuticals (TLX) Form 3?

The derivative summary in this Form 3 is empty. This means no options, warrants, or other derivative securities are listed for William R. Jellison in this particular filing, so only his status as a director is being recorded.

What does the transaction summary show in the Telix Pharmaceuticals (TLX) Form 3?

The transaction summary shows zero buy, sell, acquire, or dispose transactions, and no gifts, tax withholding, or restructuring events. Net buy-sell direction is described as neutral, confirming this filing records no trading activity for the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jellison William R

(Last) (First) (Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE 3051

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/11/2026

3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

3a. Foreign Trading Symbol
[TLX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Ex. 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Oliver Newman, on behalf of William Jellison	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)